Journal of Immunology Research

Immunotherapy and Vaccine Development


Status
Published

Lead Editor

1University of Oxford, Oxford, UK

2University of Zürich, Zürich, Switzerland

3German Cancer Research Center (DKFZ), Heidelberg, Germany


Immunotherapy and Vaccine Development

Description

The success of immune checkpoint inhibitors for the treatment of cancer represents a new era for cancer treatment. The field is currently blooming with various clinical approaches in development including chimeric antigen receptor T cell therapy and prophylactic cancer vaccines against cervical cancer. However, the side effects of these therapies and the failure to extend the success of the cervical cancer vaccines to other cancers spark more questions. A better understanding of the immunological mechanisms towards different immunotherapies and vaccination will advance the development and extend the therapies to other diseases.

We invite investigators to submit original research and review articles that will contribute to the understanding and development of immunotherapy and vaccine research. We are particularly interested in articles testing novel and effective immunotherapies, giving new insights into the mechanisms involved in the therapy.

Potential topics include but are not limited to the following:

  • T cell based immunotherapies and vaccines
  • Immunotherapy for cancer and infectious diseases
  • Immunotherapy for autoimmune diseases
  • Development of prophylactic vaccines against cancer and infectious diseases
  • Animal models for studying immunotherapies and vaccine strategies
  • Vaccine adjuvants
Journal of Immunology Research
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision121 days
Acceptance to publication27 days
CiteScore6.000
Journal Citation Indicator0.560
Impact Factor4.1
 Submit Evaluate your manuscript with the free Manuscript Language Checker

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.